Concise review : increasing the validity of cerebrovascular disease models and experimental methods for translational stem cell research
| Autor: | Björn Nitzsche, Claudia Pösel, Gesa Weise, Daniel-Christoph Wagner, Jukka Jolkkonen, Johannes Boltze, Franziska Nitzsche |
|---|---|
| Přispěvatelé: | School of Medicine / Clinical Medicine, Publica |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Aging Transferability Cerebrovascular diseases Stem cells Biology Vascular dementia Validity Cell therapy Translational Research Biomedical 03 medical and health sciences Preclinical research 0302 clinical medicine medicine Animals Humans Intensive care medicine Stroke Clinical study design QH Confounding Stem cell transplantation Cell Biology medicine.disease Stem Cell Research Reliability Animal models Cerebrovascular Disorders Disease Models Animal 030104 developmental biology Immune System Molecular Medicine Stem cell Experimental methods RB 030217 neurology & neurosurgery Developmental Biology RC |
| ISSN: | 1066-5099 |
| Popis: | Interspecies differences, anatomical and physiological aspects, as wells as simplified study designs contribute to an overestimation of treatment effects and limit the transferability of experimental results into clinical applications. Confounders of cell therapies for cerebrovascular disorders (CVD) include common CVD comorbidities, frequent medications potentially affecting endogenous and transplanted stem cells, as well as age- and immune-system–related effects. All those can contribute to a substantial modeling bias, ultimately limiting the prospective quality of preclinical research programs regarding the clinical value of a particular cell therapy. In this review, we discuss the nature and impact of most relevant confounders. We provide suggestions on how they can be considered to enhance the validity of CVD models in stem cell research. Acknowledging substantial and sometimes surprising effects of housing conditions, chronobiology, and intersex differences will further augment the translational value of animal models. We finally discuss options for the implementation of high-quality functional and imaging readout protocols. Altogether, this might help to gain a more holistic picture about the therapeutic impact of a particular cell therapy for CVD, but also on potential side and off-site effects of the intervention. Stem Cells 2017;35:1141–1153 published version peerReviewed |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text